NASDAQ:CGTX Cognition Therapeutics Q1 2025 Earnings Report $1.01 -0.02 (-1.94%) Closing price 09/8/2026 04:00 PM EasternExtended Trading$1.02 +0.01 (+0.99%) As of 07:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cognition Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.12Beat/MissMissed by -$0.02One Year Ago EPSN/ACognition Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACognition Therapeutics Announcement DetailsQuarterQ1 2025Date5/6/2025TimeBefore Market OpensConference Call DateWednesday, May 7, 2025Conference Call Time7:30AM ETUpcoming EarningsCognition Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cognition Therapeutics Earnings HeadlinesCognition Therapeutics to Present Zervimesine Development Progress at H.C. Wainwright Global Investment ConferenceSeptember 8 at 7:51 AM | quiverquant.comQCognition Therapeutics to Present at H.C. Wainwright Global Investment ConferenceSeptember 8 at 7:30 AM | globenewswire.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.September 9 at 1:00 AM | Banyan Hill Publishing (Ad)Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of "Moderate Buy" by AnalystsAugust 29, 2026 | americanbankingnews.comCognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business UpdateAugust 6, 2026 | markets.businessinsider.comCognition Therapeutics CEO Lisa Ricciardi to Participate in B. Riley Mind, Muscle & Vision Summit Fireside DiscussionJuly 13, 2026 | quiverquant.comQSee More Cognition Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cognition Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cognition Therapeutics and other key companies, straight to your email. Email Address About Cognition TherapeuticsCognition Therapeutics (NASDAQ:CGTX) is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease. CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease. In addition to its lead program, the company is advancing a preclinical pipeline aimed at expanding its approach to other neurodegenerative conditions. To support its global development efforts, Cognition Therapeutics collaborates with academic centers, contract research organizations and specialized clinical sites. Headquartered in Pittsburgh, Pennsylvania, Cognition Therapeutics conducts operations primarily in the United States, with ongoing clinical and regulatory activities in European markets. The company is led by co-founder and CEO Stephen M. Maccecchini, Ph.D., who oversees research, development and strategic partnerships. Cognition Therapeutics’ common stock is traded on the NASDAQ under the ticker symbol CGTX.View Cognition Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles PayPal’s Takeover Story Ended, But Its Turnaround Story Didn’tDespite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom StockCampbell’s Dividend Cut May Reset the Stock, But the Turnaround Still Has to DeliverQ3 Earnings Could Be the Catalyst the Market Has Been Waiting For3 AI Optical Networking Stocks Positioned for the Data Center BuildoutSafety Stocks Are Not What They Used to Be: 4 Names Built for a Weaker DollarMarketBeat Week in Review – 08/31 - 09/04 Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
